For Referring Physicians

Refer a patient. Keep the loop closed.

Nephrology, primary care, cardiology, endocrinology: if your patient has kidney disease, hypertension, or cardiorenal risk, there may be a protocol for them here, with study-related care handled by us and every result reported back to you.

Refer a patient →Open studies by condition

What Your Patient Gets · What You Keep

Research that respects the referral.

SCRI is run by the same board-certified nephrologists who practice at Nephrology Associates, PC, the region's premier site for kidney studies. We know what a specialist referral should feel like from your side of the fax machine.

Direct reporting

Physician-to-physician updates at screening, enrollment, and closeout. You are never left wondering whether your patient qualified.

Routine care continues with you

Study participation runs alongside their regular care. We manage the study-related visits only; everything else continues in your office.

No cost to the patient

Study visits, tests, and the investigational therapy are provided at no charge. Insurance is never billed for study-related care.

IRB oversight

Every protocol is approved and monitored by an Institutional Review Board before a participant is enrolled.

Certified coordinators

GCP-trained, ACRP-certified research coordinators, a dedicated regulatory specialist, and on-site pharmacy and lab management.

Investigators who publish

Board-certified nephrologists published in NEJM and leading journals (SPRINT, DAPA-CKD, vadadustat), several serving as medical directors of area dialysis centers.

How It Works

Three steps, and you hear back.

Send us the clinical picture. We match it against every open protocol, contact the patient with your knowledge, and report the outcome to your office.

Refer a patient → Call (706) 922-3005

Send the referral

Use the form below, call the study team, or fax the clinical summary to (706) 722-5843. Keep identifiers off the web form. Fax or phone those.

We screen against open protocols

A coordinator reviews the history against current inclusion criteria and calls the patient to explain the study and answer questions.

You get the answer

Whether the patient enrolls or not, your office hears back directly. Enrolled patients continue seeing you for everything outside the protocol.

Consider a Referral For

Open studies by condition

Populations are as stated by each sponsor. Final eligibility is confirmed by the study team against the full protocol.

Enrolling

CKD & High Blood Pressure

Baxdrostat in combination with dapagliflozin, evaluated for renal outcomes and cardiovascular mortality in chronic kidney disease (BaxDuo-Pacific).

Who it is forAdults with chronic kidney disease and high blood pressure.

AstraZeneca·NephrologyAsk about this study →

Enrolling

IgA Nephropathy

Extended TARPEYO® (delayed-release budesonide) treatment in adults with primary IgA nephropathy (NefXtend).

Who it is forAdults with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg.

Calliditas·NephrologyAsk about this study →

Broader experience across CKD, diabetic kidney disease, IgA nephropathy, anemia of CKD, polycystic kidney disease, resistant hypertension, and dialysis. See the completed-study history.

A coordinator reviewing a study binder — Screening against every open protocol

Regulatory binders at SCRI — Dedicated regulatory

The SCRI sign in the meeting room — Weekly research meeting

Refer a Patient

Start the conversation

Clinical context only on this form: no names, dates of birth, or record numbers. We will call your office to coordinate the rest, or you can fax the summary directly.

We call your office to coordinate the referral
Patient contacted only with your knowledge
Outcome reported back to you either way

Study team(706) 922-3005

Fax referrals(706) 722-5843

Email[email protected]

Who You Are Referring To

Practicing nephrologists, led by Dr. Matthew Diamond, DO, FASN, FACP

Every investigator sees patients at Nephrology Associates, PC. Your patient is evaluated by a specialist, not a study desk.

Medical Director · Southeastern Clinical Research Institute

Dr. Matthew DiamondDO, FASN, FACP

Former Professor of Medicine at the Medical College of Georgia and a SPRINT site investigator, published in the New England Journal of Medicine on intensive blood-pressure control and chronic kidney disease. A Fellow of both the American Society of Nephrology and the American College of Physicians, he directs every study SCRI runs.